Finerenone in Patients With Chronic Kidney Disease and Type 2 Diabetes by Sodium-Glucose Cotransporter 2 Inhibitor Treatment: The FIDELITY Analysis.

Peter Rossing,Stefan D Anker,Gerasimos Filippatos,Bertram Pitt,Luis M Ruilope,Andreas L Birkenfeld,Janet B McGill,Sylvia E Rosas,Amer Joseph,Martin Gebel,Luke Roberts,Markus F Scheerer,George L Bakris,Rajiv Agarwal

Diabetes care（2022）

引用 29|浏览16

暂无评分

摘要

Benefits of finerenone compared with placebo on cardiorenal outcomes in patients with CKD and type 2 diabetes were observed irrespective of SGLT2i use.

查看译文

关键词

sodium–glucose cotransporter,chronic kidney disease,diabetes,inhibitor treatment

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要